Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictors of immune checkpoint inhibitor-induced colitis
NL-OMON53776Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nivolumab, pembrolizumab, atezolizumab and ipilimumab in cancer (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Incidence of immune checkpoint inhibitor-mediated colitis, Time to severe immune checkpoint inhibitor-mediated colitis and 2 more. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON53776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53776.